Revision as of 15:03, 27 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,644 edits created drug stubTag: nowiki added | Latest revision as of 16:37, 27 December 2024 edit undoIdoghor Melody (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers32,603 editsm clean up, added orphan tagTag: AWB | ||
Line 1: | Line 1: | ||
{{Orphan|date=December 2024}} | |||
{{cs1 config|name-list-style=vanc|display-authors=6}} | {{cs1 config|name-list-style=vanc|display-authors=6}} | ||
Line 19: | Line 20: | ||
| widthR = | | widthR = | ||
| altR = | | altR = | ||
| captionLR = |
| captionLR = | ||
<!-- Clinical data --> | <!-- Clinical data --> | ||
Line 40: | Line 41: | ||
| ATC_prefix = | | ATC_prefix = | ||
| ATC_suffix = | | ATC_suffix = | ||
| ATC_supplemental = |
| ATC_supplemental = | ||
<!-- Legal status --> | <!-- Legal status --> | ||
Line 61: | Line 62: | ||
| legal_UN = | | legal_UN = | ||
| legal_UN_comment = | | legal_UN_comment = | ||
| legal_status = |
| legal_status = | ||
<!-- Pharmacokinetic data --> | <!-- Pharmacokinetic data --> | ||
Line 71: | Line 72: | ||
| elimination_half-life = | | elimination_half-life = | ||
| duration_of_action= | | duration_of_action= | ||
| excretion = |
| excretion = | ||
<!-- Identifiers --> | <!-- Identifiers --> | ||
Line 113: | Line 114: | ||
== References == | == References == | ||
{{reflist}} | {{reflist}} | ||
⚫ | {{pharma-stub}} | ||
] | ] | ||
Line 124: | Line 123: | ||
] | ] | ||
] | ] | ||
⚫ | {{pharma-stub}} |
Latest revision as of 16:37, 27 December 2024
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024) |
Pharmaceutical compound
Clinical data | |
---|---|
Other names | AG-7404, V-7404 |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H29N5O7 |
Molar mass | 523.546 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Imocitrelvir is an investigational new drug that is being evaluated for the treatment of viral infections. It is a 3C protease inhibitor in picornaviruses. Originally developed by Pfizer for treating human rhinovirus infections, this small molecule has shown promise against a broader range of viruses, including polioviruses.
References
- "Imocitrelvir". PatSnap.
- Xie H, Rhoden EE, Liu HM, Ogunsemowo F, Mainou BA, Burke RM, et al. (November 2024). "Antiviral Development for the Polio Endgame: Current Progress and Future Directions". Pathogens. 13 (11). Basel, Switzerland: 969. doi:10.3390/pathogens13110969. PMC 11597170. PMID 39599522.
- Bandyopadhyay AS, Burke RM, Hawes KM (June 2024). "Polio Eradication: Status, Struggles and Strategies". The Pediatric Infectious Disease Journal. 43 (6): e207-211. doi:10.1097/INF.0000000000004330. PMID 38564755.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |